ArticleEClinicalMedicine2021

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naïve Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trial.

Dongyang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.